1. Kapecitabin med obsevanjem : bolnikov dnevnikJanja Ocvirk, Vaneja Velenik, Irena Oblak, Franc Anderluh, Jasna But-Hadžić, Ajra Šečerov Ermenc, Martina Reberšek, Marko Boc, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Tanja Mesti, 2014, ni določena Ključne besede: citostatiki, kapecitabin, bolniki, obsevanje
Objavljeno v DiRROS: 02.09.2025; Ogledov: 621; Prenosov: 253
 Povezava na datoteko |
2. Kapecitabin pri zdravljenju bolnikov z rakom : bolnikov dnevnikJanja Ocvirk, Martina Reberšek, Marko Boc, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Tanja Mesti, 2023, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: citostatiki, kapecitabin, bolniki
Objavljeno v DiRROS: 08.08.2025; Ogledov: 772; Prenosov: 268
Povezava na datoteko |
3. Liposomski irinotekan za zdravljenje napredovalega raka trebušne slinavkeJanja Ocvirk, Martina Reberšek, Tanja Mesti, Neva Volk, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2023, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak trebušne slinavke, kemoterapija, onkološko zdravljenje
Objavljeno v DiRROS: 08.08.2025; Ogledov: 964; Prenosov: 260
Povezava na datoteko |
4. Trifluridin/tipiracil za zdravljenje razširjenega raka debelega črevesa in danke in raka želodca : dnevnik za bolnikaJanja Ocvirk, Martina Reberšek, Tanja Mesti, Neva Volk, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2023, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak debelega črevesa, rak danke, razširjeni rak, kemoterapija, bolniki, navodila
Objavljeno v DiRROS: 08.08.2025; Ogledov: 693; Prenosov: 259
Povezava na datoteko |
5. Priporočila za sistemsko onkološko in radioterapevtsko zdravljenje rakov biliarnega traktaErik Brecelj, Martina Reberšek, Ajra Šečerov Ermenc, Vesna Zadnik, Maja Ebert Moltara, Nežka Hribernik, Peter Korošec, Tanja Mesti, Janja Ocvirk, Franc Anderluh, Marko Boc, Marija Ignjatović, Ana Jeromen, Irena Oblak, Vaneja Velenik, Jelena Azarija, Neva Volk, Nena Golob, 2025, strokovni članek Povzetek: Raki biliarnega trakta so redka in heterogena skupina z naraščajočo incidenco in visoko umrljivostjo. Imajo slabo prognozo s celokupnim preživetjem manj od 1 leta. Nova dognanja o molekularno genetski heterogenosti rakov biliarnega trakta in novi terapevtskih pristopi omogočajo tem bolnikom daljša preživetja in boljšo kvaliteto življenja. V Priporočilih so predstavljena najnovejša priporočila za sistemsko onkološko zdravljenje in radioterapijo te skupine rakov, med katere po mednarodnih propročilih sedaj prištevamo karcinom žolčnika, intrahepatalne holangiokarcinome in ekstrahepatične holangiokarcinome, s perihilarnim holangiokarcinomom in karcinomom distalnega žolčevoda. Priporočila za sistemsko zdravljenje so povzeta in pripravljena na podlagi mednarodnih priporočil, ameriških, National Comprehensive Cancer Network (NCCN) in evropskih, Evropskega združenja za internistično onkologijo – European Society of Medical oncology (ESMO).
Ključne besede: raki biliarnega trakta, sistemsko zdravljenje, priporočila
Objavljeno v DiRROS: 18.07.2025; Ogledov: 863; Prenosov: 348
 Celotno besedilo (125,57 KB) |
6. Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer : single center experienceJanja Ocvirk, Maja Ebert Moltara, Tanja Mesti, Marko Boc, Martina Reberšek, Neva Volk, Jernej Benedik, Zvezdana Hlebanja, 2016, izvirni znanstveni članek Povzetek: Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim of the study was with the help of the patients% register to determine the safety and efficacy of bevacizumab plus chemotherapy in elderly patients who had previously untreated metastatic colorectal cancer. Patients and methods. The registry of patients with mCRC was designed to prospectively evaluate the safety and efficacy of bevacizumab-containing chemotherapy as well as selection of patients in routine clinical practice. Patient baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected, evaluated and compared according to the age categories. Results. Between January 2008 and December 2010, 210 patients with mCRC (median age 63, male 61.4%) started bevacizumab-containing therapy in the 1st line setting. Majority of the 210 patients received irinotecan-based chemotherapy (68%) as 1st line treatment and 105 patients (50%) received bevacizumab maintenance therapy. Elderly (% 70 years) patients presented 22.9% of all patients and they had worse performance status (PS 1/2, 62.4%) than patients in < 70 years group (PS 1/2, 35.8%). Difference in disease control rate was mainly due to inability to assess response in elderly group (64.6% in elderly and 77.8% in < 70 years group, p = 0.066). The median progression free survival was 10.2 (95% CI, 6.7%16.2) and 11.3 (95% CI, 10.2%12.6) months in elderly and < 70 years group, respectively (p = 0.58). The median overall survival was 18.5 (95% CI, 12.4%28.9) and 27.4 (95% CI, 22.7%31.9) months for elderly and < 70 years group, respectively (p = 0.03). Three-year survival rate was 26% and 37.6% in elderly vs. < 70 years group (p = 0.03). Overall rates of bevacizumab-related adverse events were similar in both groups: proteinuria 21/22 %, hypertension 25/19 %, haemorrhage 2/4 % and thromboembolic events 10/6 %, for elderly and < 70 years group, respectively. Conclusions. In routine clinical practice, the combination of bevacizumab and chemotherapy is effective and welltolerated regimen in elderly patients with metastatic colorectal cancer.
Ključne besede: metastatic colorectal cancer, bevacizumab, chemotherapy, elderly
Objavljeno v DiRROS: 30.04.2024; Ogledov: 1509; Prenosov: 549
Celotno besedilo (620,74 KB) |
7. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer : a single institution retrospective analysisMartina Reberšek, Marko Boc, Petra Škerl, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novaković, Janja Ocvirk, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), debelo črevo, danka, zdravljenje
Objavljeno v DiRROS: 18.03.2024; Ogledov: 1832; Prenosov: 494
Celotno besedilo (461,04 KB) |
8. |
9. |
10. |
